TY - JOUR
T1 - Immune parameters affecting the efficacy of chemotherapeutic regimens
AU - Zitvogel, Laurence
AU - Kepp, Oliver
AU - Kroemer, Guido
N1 - Funding Information:
G. Kroemer is supported by the Ligue Nationale contre le Cancer (Equipes labelisée), Agence Nationale pour la Recherche, European Commission (Active p53, Apo‑Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Médicale, Institut National du Cancer and Cancéropôle Ile‑de‑France.
PY - 2011/3/1
Y1 - 2011/3/1
N2 - The outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells by causing them to elicit an immune response or alternatively, by increasing their susceptibility to immune attack. In addition, chemotherapy can stimulate anticancer immune effectors either in a direct fashion or by subverting immunosuppressive mechanisms. Beyond cancer-cell-intrinsic factors that determine the cytotoxic or cytostatic response, as well as the potential immunogenicity of tumor cells, the functional state of the host immune system has a major prognostic and predictive impact on the fate of cancer patients treated with conventional or targeted chemotherapies. In this Review, we surmise that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses.
AB - The outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells by causing them to elicit an immune response or alternatively, by increasing their susceptibility to immune attack. In addition, chemotherapy can stimulate anticancer immune effectors either in a direct fashion or by subverting immunosuppressive mechanisms. Beyond cancer-cell-intrinsic factors that determine the cytotoxic or cytostatic response, as well as the potential immunogenicity of tumor cells, the functional state of the host immune system has a major prognostic and predictive impact on the fate of cancer patients treated with conventional or targeted chemotherapies. In this Review, we surmise that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses.
UR - http://www.scopus.com/inward/record.url?scp=79952390627&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2010.223
DO - 10.1038/nrclinonc.2010.223
M3 - Article
C2 - 21364688
AN - SCOPUS:79952390627
SN - 1759-4774
VL - 8
SP - 151
EP - 160
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 3
ER -